The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
NCT03576807
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Relapsed or Refractory B-cell Lymphomas
Interventions
DRUG:
CD20 CAR-T cells
Sponsor
Xin Wang